BRAF and melanoma: Although BRAF mutations are more frequent in melanoma and papillary thyroid carcinoma in comparison with CRC, a few studies analyzed the effects of BRAF inhibitors (vemurafenib or dabrafenib and trametinib) in patients with metastatic CRC.